C. S. Gal

发表

Automation of deburring process using vision sensor and TSK fuzzy model

D. S. Ahn, S. W. Shin, C. S. Gal, 1996 .

Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.

C. S. Gal, G. Griebel, P. Soubrié, 2005, Current pharmaceutical design.

Biochemical and Pharmacological Properties of SR 49059 , a New , Potent , Nonpeptide Antagonist of Rat and Human Vasopressin Via Receptors

Ala, C. S. Gal, S., 2022 .

The cloned guinea pig neuropeptide Y receptor Y1 conforms to other mammalian Y1 receptors

C. S. Gal, D. Larhammar, J. Maffrand, 1999, Peptides.

Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells. An endothelin B receptor-mediated pathway.

C. S. Gal, D. Dhumeaux, A. Mallat, 1995, The Journal of clinical investigation.

Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats.

C. S. Gal, W. Jiménez, M. Morales-Ruiz, 2000, The Journal of pharmacology and experimental therapeutics.

Nonpeptide Antagonists for Vasopressin Receptors

C. S. Gal, 1998 .

Effects of SR 49059, a non‐peptide antagonist of vasopressin V1a receptors, on vasopressin‐induced coronary vasoconstriction in conscious rabbits

C. S. Gal, G. Fur, J. Maffrand, 1995, Fundamental & clinical pharmacology.

SR 120819A or the first Generation of orally active Y1-receptor antagonists

C. S. Gal, 1997 .

CNS Drug Reviews

C. S. Gal, G. Griebel, J. Wagnon, 2005 .

Chapter 4.2 – Nonpeptide vasopressin V1b receptor antagonists

C. S. Gal, G. Griebel, 2005 .

Importance of the phenotypic state of vascular smooth muscle cells on the binding and the mitogenic activity of endothelin

C. S. Gal, J. Herbert, J. Maffrand, 1991, Peptides.

Single Amino Acid Substitutions and Deletions That Alter the G Protein Coupling Properties of the V2 Vasopressin Receptor Identified in Yeast by Receptor Random Mutagenesis*

C. S. Gal, J. Wess, E. Kostenis, 2001, The Journal of Biological Chemistry.

Differential Sensitivity to Cardiotonic Drugs of Cyclic AMP Phosphodiesterases Isolated from Canine Ventricular and Sinoatrial‐Enriched Tissues

C. S. Gal, C. Lugnier, J. Stoclet, 1989, Journal of cardiovascular pharmacology.

Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist.

C. S. Gal, 1998 .

Vasopressin Does Not Mediate Hypersensitivity of the Hypothalamic Pituitary Adrenal Axis during Chronic Stress

C. S. Gal, S. Lightman, S. Subburaju, 2008, Annals of the New York Academy of Sciences.

Characterization of a functional V 1B vasopressin receptor in the male rat kidney, evidence for crosstalk between V 1B and V 2 receptor signaling pathways

C. S. Gal, G. Guillon, C. Llorens-Cortes, 2022 .

Pro-inflammatory role of vasopressin through V 1 b receptors in hapten-1 induced experimental colitis in rodents : implication in IBD 2 3 4 Running head : Vasopressin in experimental colitis 5 6 7

C. S. Gal, M. Pascal, A. Schulte, 2010 .

An overview of SR121463, a selective non-peptide vasopressin V2 receptor antagonist

C. S. Gal, C Serradeil Le Gal, 2006 .

The vasopressin V1b receptor as a therapeutic target in stress-related disorders.

C. S. Gal, G. Griebel, J. Simiand, 2003, Current drug targets. CNS and neurological disorders.

The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations

C. S. Gal, G. Guillon, S. Stoev, 2004, Journal of neuroendocrinology.

Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

C. S. Gal, J. Maffrand, J. Wagnon, 1993, The Journal of clinical investigation.

Key amino acids located within the transmembrane domains 5 and 7 account for the pharmacological specificity of the human V1b vasopressin receptor.

C. S. Gal, D. Rognan, G. Guillon, 2004, Molecular endocrinology.

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

C. S. Gal, G. Fur, L. Bankir, 1996, The Journal of clinical investigation.